Jasper Net Income Per E B T from 2010 to 2024
| JSPRW Stock | USD 0.22 0.01 4.76% |
Net Income Per E B T | First Reported 2010-12-31 | Previous Quarter 0.97536804 | Current Value 0.64 | Quarterly Volatility 0.0741112 |
Check Jasper Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Jasper Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.2 M, Selling General Administrative of 11.2 M or Other Operating Expenses of 40 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.1. Jasper financial statements analysis is a perfect complement when working with Jasper Therapeutics Valuation or Volatility modules.
Jasper | Net Income Per E B T |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Jasper Stock Analysis
When running Jasper Therapeutics' price analysis, check to measure Jasper Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jasper Therapeutics is operating at the current time. Most of Jasper Therapeutics' value examination focuses on studying past and present price action to predict the probability of Jasper Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jasper Therapeutics' price. Additionally, you may evaluate how the addition of Jasper Therapeutics to your portfolios can decrease your overall portfolio volatility.